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Abstract
Previously, we reported on the target cell–restricted
fratricide apoptotic activity of scFvC54:sTRAIL, a fu-
sion protein comprising human-soluble tumor necro-
sis factor–related apoptosis-inducing l igand (TRAIL)
genetically linked to the antibody fragment scFvC54
specific for the cell surface target antigen EGP2. In the
present study, we report that the selective binding of
scFvC54:sTRAIL to EGP2-positive target cells conveys
an exceptionally potent pro–apoptotic effect toward
neighboring tumor cells that are devoid of EGP2 ex-
pression (bystander cells). The anti–tumor bystander
activity of scFvC54:sTRAIL was detectable at target-to-
bystander cell ratios as low as 1:100. Treatment in the
presence of EGP2-blocking or TRAIL-neutralizing anti-
body strongly inhibited apoptosis in both target and
bystander tumor cells. In the absence of target cells,
bystander cell apoptosis induction was abrogated.
The bystander apoptosis activity of scFvC54:sTRAIL
did not require internalization, enzymatic conversion,
diffusion, or communication (gap junctional intracel-
lular communication) between target and bystander
cells. Furthermore, scFvC54:sTRAIL showed no de-
tectable signs of innocent bystander activity toward
freshly isolated blood cells. Further development of
this new principle is warranted for approaches where
cancer cells can escape from antibody-based therapy
due to partial loss of target antigen expression.
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Introduction
In recent years, several antibody-based therapies that tar-
get tumor-associated membrane antigens have entered
clinical trials with promising results [1–3]. However, curative
treatment is frequently not achieved due to therapy-resistant
recurrences emerging after initial rounds of seemingly
successful treatment [4–6]. It has been shown that within
one tumor mass, different stages of malignant progres-
sion and various oncogenic mutations can occur simulta-
neously, leading to the development of heterogeneous
tumor cell phenotypes [7–12]. Heterogeneous and lost target
antigen expression are likely to be responsible for many of
the therapeutic failures observed in current antibody-based
therapies [4–6].
Therefore, strategies have been developed to take advan-
tage of the so-called ‘‘bystander effect,’’ which aims to elimi-
nate tumor cells with reduced or lost target antigen expression.
The bystander effect is based on the principle that targeted
tumor cells are not only eliminated, but are also exploited to
convey the therapeutic effect toward neighboring tumor cells
devoid of target antigen expression. Bystander effects have
been described for several antibody-based therapeutic
approaches [13,14] and, more recently, for gene therapy using
FasL and tumor necrosis factor– related apoptosis-inducing
l igand (TRAIL)—two members of the tumor necrosis family
of death-inducing ligands [15–18].
TRAIL is of particular interest for its tumor-restricted apo-
ptosis-inducing capacity in a wide range of neoplastic cells
while sparing normal tissues. TRAIL is expressed as a type II
transmembrane protein (memTRAIL) [19,20] on a broad spec-
trum of tissues ranging from peripheral blood lymphocytes,
spleen, and thymocytes to many solid organs, but is absent in
the brain, liver, and testis.
A unique TRAIL receptor system has been uncovered in
which the distinct receptors TRAIL-R1, TRAIL-R2, TRAIL-R3,
TRAIL-R4, and osteoprotegerin (OPG) can differentially bind
and interact with TRAIL. After ligation, TRAIL-R1 and TRAIL-
R2 recruit the intracellular Fas-associated death domain
Abbreviations: TRAIL, tumor necrosis factor – related apoptosis-inducing ligand; scFv, single-
chain fragment of variable regions; EGP2, epithelial glycoprotein 2; EGFP, enhanced green
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(FADD) adapter protein and the initiator caspase-8 or cas-
pase-10, thereby forming the death-inducing signaling com-
plex (DISC) [21–28]. Assembly of the DISC results in
activation of caspase-8 or caspase-10, which subsequently
cleaves and activates effector caspases such as caspase-3,
caspase-6, and caspase-7, leading to poly(ADP-ribose) po-
lymerase (PARP) cleavage and, ultimately, apoptotic cell
death. TRAIL-R3, TRAIL-R4, and OPG lack (functional)
death domains and, after ligation, do not induce apoptosis.
TRAIL-R1 and TRAIL-R2 have a broad and partly over-
lapping pattern of expression, suggesting that they may
serve as an alternate or ‘‘backup’’ system, allowing the
immune system to control aberrant cells even if one of the
receptors has failed. Recently, it was shown that TRAIL-R1
and TRAIL-R2 have rather distinct cross-linking require-
ments for the initiation of apoptosis [29]. Both recombinant
soluble TRAIL (sTRAIL), consisting of the extracellular do-
main of TRAIL, and memTRAIL can efficiently activate
TRAIL-R1 even at low concentrations, whereas TRAIL-R2
can only be activated by memTRAIL or sTRAIL that is sec-
ondarily cross-linked by antibodies.
To date, various forms of recombinant sTRAIL have been
generated, of which potent anti– tumor activity has been
demonstrated in several xenograft mouse models of human
cancers, including colorectal cancer [30,31], glioblastoma
[31], and breast cancer [32]. These sTRAIL preparations
have retained the selective apoptotic activity toward trans-
formed cells, but lack an intrinsic targeting capacity that
allows for preferential binding to TRAIL receptors expressed
on tumor cells. Moreover, sTRAIL is not very effective in
signaling apoptosis in tumor cells that predominantly express
TRAIL-R2.
It has been shown that cross-linking of agonistic TRAIL
receptors is required to efficiently obtain cell death. In a
previous report, Wajant et al. [33] demonstrated that the
signaling capacity of sTRAIL for TRAIL-R2 could be restored
by genetic fusion to a recombinant antibody fragment (sin-
gle-chain fragment of variable regions, or scFv) recognizing
the tumor stroma marker fibroblast activation protein (FAP).
Independently, we developed a TRAIL fusion protein, des-
ignated scFvC54:sTRAIL, in which the human scFv antibody
fragment C54 is genetically linked to the N-terminus of
human sTRAIL [34]. The high-affinity scFvC54 antibody
domain specifically targets EGP2 [also known as epithelial
cell adhesion molecule (Ep-CAM), or CO17-1a antigen], an
established cell surface target antigen overexpressed in a
variety of carcinomas. Selective binding to EGP2 results in
accretion of scFvC54:sTRAIL at the cell surface of targeted
cells only, converting soluble scFvC54:sTRAIL into a mem-
brane-bound form of TRAIL. Subsequently, a surplus of
sTRAIL domains displayed on the target cell surface is
available for the cross-linking of TRAIL-R2 on neighboring
tumor cells, resulting in efficient and target antigen-restricted
reciprocal fratricide apoptosis induction. In the present study,
we analyzed whether targeting of scFvC54:sTRAIL to EGP2-
positive cells can be used to convey a pro–apoptotic by-
stander effect toward neighboring tumor cells devoid of
EGP2 expression, as schematically depicted in Figure 1.
Interestingly, we observed an exceptionally potent bystander
apoptotic effect of scFvC54:sTRAIL, which critically
depended on the presence of EGP2-positive target cells.
Bystander apoptosis induction by scFvC54:sTRAIL might be
applicable for the treatment of human cancer cells that
escape current antibody-based therapy due to partial loss
of target antigen expression.
Materials and Methods
Monoclonal Antibodies (MAbs) and scFv Antibody Fragment
MAb MOC31 is a murine IgG1 with high-affinity specificity
for human EGP2 [35]. MAb MOC31 was directly labeled with
phycoerythrin (PE), yielding MOC31-PE using standard pro-
cedures. The anti–EGP2 scFvC54 (kindly provided by Prof.
T. Logtenberg, Utrecht University, Utrecht, The Netherlands)
has been previously selected from a large semisynthetic
phage display library with random human VH–VL pairings
and has a VH(G4S)3–VL format [36]. MAb MOC31 and
scFvC54 compete for binding to the same epitope on the
extracellular domain of EGP2. A multimeric form of the
extracellular domain of EGP2 (sEGP2) was produced and
purified as described previously [37]. Where indicated, multi-
meric sEGP2 was used to secondari ly cross-l ink
scFvC54:sTRAIL. TRAIL-neutralizing MAb 2E5 was pur-
chased from Alexis (Kordia Life Sciences, Leiden, The
Netherlands). MAb 2E5 neutralizes TRAIL activity by binding
to an epitope on the extracellular domain of TRAIL that
inhibits binding to the various TRAIL receptors.
Cell Lines and EGP2 Transfectants
Human cell lines Jurkat (acute lymphoblastic T-cell leuke-
mia), Ramos (B-cell lymphoma), and U87MG (glioblastoma),
all of which are EGP2-negative, were purchased from the
Figure 1. Target cell and bystander cell apoptosis induction by
scFvC54:sTRAIL. Binding of scFvC54:sTRAIL to the abundantly expressed
target antigen EGP2 (E) results in immobilization of scFvC54:sTRAIL at the
cell surface of EGP2-positive cells only. Subsequently, membrane-bound
scFvC54:sTRAIL induces fratricide apoptosis by reciprocal cross-linking of
TRAIL-R1/R2 (T) on neighboring EGP2-positive target cells. Analogously,
immobilized scFvC54:sTRAIL on target cells can induce cross-linking of
agonistic TRAIL receptors on the cell surface of a neighboring tumor cell
devoid of EGP2 expression, resulting in apoptosis induction of one or more
bystander cells (diagram is not to scale).
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ATCC (Manassas, VA). EGP2-positive variants of the above
cell lines were generated by retroviral transduction. In short,
EGP2 cDNA was cloned into a retroviral vector derivative of
LZRS-pBMN-lacZ [38] (kindly provided by Dr. G. Nolan,
Stanford University School of Medicine, San Francisco,
CA), yielding LZRS-EGP2-IRES-EGFP. To produce retrovi-
ral particles, LZRS-EGP2-IRES-EGFP was transfected into
the amphotrophic packaging cell line Phoenix, using Fugene-6
transfection reagent according to the manufacturer’s recom-
mendations (Roche Diagnostics, Almere, The Netherlands).
Transfected cells were selected by culturing in the presence
of 1 mg/ml puromycin, 300 mg/ml hygromycin, and 1 mg/ml
diphtheria toxin (BD Biosciences Clontech, Palo Alto, CA).
Viral particle-containing supernatant was harvested after 3
days and used to transduce Jurkat, Ramos, and U87MG
cells. After overnight incubation, viral particle–containing
supernatant was replaced by fresh medium. Transduced
cells were subsequently sorted for simultaneous enhanced
green fluorescent protein (EGFP) fluorescence and EGP2
expression as detected by MOC31-PE using the MoFlo high-
speed cell sorter (Cytomation, Fort Collins, CO). Analogous
methods were employed to generate c-FLIPL–encoding
retroviral particles, which were used to transduce Ramos
cells. Ectopic overexpression of c-FLIPL in Ramos.c-FLIPL–
transduced cells was confirmed by immunoblotting of intra-
cellular protein extracts. All cell lines were cultured at 37jC in
humidified 5% CO2 atmosphere. Suspension cell lines
(Jurkat, Jurkat.EGP2, Ramos, Ramos. EGP2, and
Ramos.c-FLIPL) were cultured in RPMI (Cambrex, East
Rutherford, NJ) supplemented with 15% fetal calf serum
(FCS). Adherent cell lines (U87MG and U87MG.EGP2) were
cultured in DMEM (Cambrex) supplemented with 10% FCS.
Expression of TRAIL Receptors
Membrane expression levels of TRAIL receptors 1, 2, 3,
and 4 were analyzed by flow cytometry using a TRAIL
receptor antibody kit purchased from Alexis. Briefly, cells
were harvested, washed using serum-free RPMI, and resus-
pended in 100 ml of fresh medium containing the appropriate
primary MAb. Specific binding of the primary antibody was
detected using a PE-conjugated secondary antibody (DAKO,
Glostrup, Denmark). All antibody incubations were per-
formed at 0jC for 45 minutes and were followed by two
washes with serum-free medium.
Production of scFvC54:sTRAIL
The fusion protein scFvC54:sTRAIL, comprising the
scFvC54 targeting domain, an intrachain linker, and the
sTRAIL effector domain, was produced in Chinese hamster
ovary (CHO-K1) cells as previously described [34]. Briefly,
the expression plasmid pEE14scFvC54:sTRAIL was trans-
fected to CHO-K1 cells, after which cells were selected for
amplified medium secretion of the fusion protein using the
glutamine synthetase method as described before [39].
Single cell sorting of transfectants using the MoFlo high-
speed cell sorter (Cytomation) identified CHO-K1 clone
70C1 that stably secreted 3.44 mg/ml scFvC54:sTRAIL into
the culture medium. Using the same procedures, mock-
scFvH22:sTRAIL, directed at the antigen CD64 not present
on the cell lines used in this study, was generated and added
in experiments where indicated.
Apoptosis Induction Assessed by Viability Assay
Where indicated, apoptosis induction apparent from loss
of tumor cell viability was assessed by MTS ([3-(4,5-dime-
thylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfo-
phenyl]-2H-tetrazolium, inner salt) assay (Promega Benelux
BV, Leiden, The Netherlands). Briefly, cells were seeded in
flat-bottom 96-well microculture plates at a density of 3 104
cells/well in 100 ml of medium. After overnight culture, spent
medium was removed and replaced by 200 ml of medium
containing various experimental conditions. After 16 hours,
MTS assay was performed according to the manufacturer’s
recommendations. Experimental apoptosis induction was
quantified as the percentage apoptosis compared to medium
control, which was set at 0% apoptosis. Each experimental
and control group consisted of six independent wells.
Apoptosis Induction Assessed by Loss of Mitochondrial
Membrane Potential (Dw)
Where indicated, apoptosis inductionapparent from lossof
Dw was analyzed using the cell-permeant green fluorescent
lipophilic dye DiOC6 (Molecular Probes, Eugene, OR) as
previouslydescribed [40]. In short, after 16hoursof treatment,
cells were harvested by centrifugation (1200g, 5minutes) and
incubated for 30 minutes at 37jC with fresh medium contain-
ing 0.1 mM DiOC6, washed twice with phosphate-buffered
saline (PBS), and analyzed using flow cytometry.
Immunoblot Analysis of Caspase Activation and PARP
Cleavage
Where indicated, apoptosis induction apparent from cas-
pase-8 and caspase-3 activation and PARP degradation was
assessed by immunoblot analysis using antibodies against
active caspase-8 (Cell Signaling Technology, Beverly, MA),
active caspase-3 (BD Biosciences, San Jose, CA), and
PARP (Santa Cruz Biotechnology, Santa Cruz, CA) respec-
tively. Briefly, cells were seeded in six-well plates at a final
concentration of 0.5  106 cells/ml and treated as indicated.
Cells were harvested by centrifugation (2000g, 10 minutes),
lysed in lysis buffer (20 mM Tris–HCl, 5.0 mMEDTA, 2.0 mM
EGTA, 100 mM NaCl, 0.05% SDS, 0.50% NP-40, 1 mM
PMSF, 10 mg/ml aprotein, 10 mg/ml leupeptin, pH 6.8), and
sonicated on ice for 2  5 seconds. Cleared supernatants
were collected after centrifugation (15,000g, 10 minutes)
and protein concentration was determined using the Brad-
ford method according to the manufacturer’s instructions
(BioRad, Hercules, CA). Samples were diluted 1:1 in stan-
dard SDS/PAGE loading buffer containing 2-mercapto-eth-
anol and boiled for 10 minutes. Samples of 30 mg of total
protein were loaded and separated using 10% acrylamide
SDS-PAGE, followed by electroblot transfer to nitrocellulose.
Blots were incubated with the respective primary MAbs and
appropriate HRPO-conjugated secondary antibodies. Spe-
cific binding of MAbs was detected using ECL (Roche
Diagnostics, Indianapolis, IN). All antibody incubations were
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performed at room temperature for 1.5 hours in PBS con-
taining 5% bovine serum albumin, followed by three washes
with PBS containing 0.1% Tween 20.
Distinctive Fluorescent Labeling of Target and Bystander
Cells
Differential cell membrane labeling of target and bystand-
er cells was achieved using the Vybrant Multicolor Cell-
Labeling kit (Molecular Probes). EGP2-negative bystander
cells were labeled with the red fluorescent dye DiI, whereas
the corresponding EGP2-positive target cells were not la-
beled. Briefly, labeling was performed by incubation of
bystander cells (1  106 cells/ml in serum-free medium) with
5 mM DiI (37jC, 5 minutes) followed by three subsequent
washes with medium (1200g, 5 minutes). Pellet was resus-
pended in medium whereupon the DiI-labeled bystander
cells were mixed with nonlabeled target cells at the target-
to-bystander ratios indicated at a final concentration of 0.5 
106 cells/ml. Differential membrane fluorescent character-
istics allow the target and bystander cells to be separately
evaluated in mixed culture after treatment.
Distinctive Quantification of Apoptosis in Target and
Bystander Cells by Loss of Dw
Nonlabeled target cells and DiI-labeled bystander cells
were mixed, at the indicated ratios, at a final concentration of
0.5 106 cells/well in a 12-well plate. After overnight culture,
cell mixtures were treated with scFvC54:sTRAIL (300 ng/ml)
for 16 hours in the presence or absence of MAb MOC31
(5 mg/ml), caspase-8 inhibitor Z-IETD-FMK (1 mg/ml) (Cal-
biochem, San Diego, CA), or TRAIL-neutralizing MAb 2E5
(1 mg/ml). The differential fluorescent characteristics of target
and bystander cells were subsequently used to separately
evaluate the amount of apoptosis induced in target and
bystander cells by measuring the loss of Dw with the fluo-
rescent dye DiOC6, as described above.
Fluorescence-Activated Cell Sorting (FACS) Sorting of
Target and Bystander Cells After Treatment
FACS sorting was applied to separate mixed target cells
and bystander cells after treatment with scFvC54:sTRAIL.
To this end, DiI-labeled bystander cells (Jurkat) were mixed
with an equal amount of unlabeled target cells (Jurkat.EGP2)
at a final concentration of 0.5  106 cells/ml. This mixed
cell culture was treated with scFvC54:sTRAIL (300 ng/ml)
for 6 hours in the presence or absence of MAbs MOC31
(5 mg/ml) or 2E5 (1 mg/ml). After treatment, cell mixtures were
collected and washed twice in fresh medium precooled at
0jC. Subsequently, 2.5  106 cells of both the target and
bystander cells were sorted using the MoFlo high-speed cell
sorter. The sorted cells were found to be >99% pure and
were separately analyzed for apoptotic features by immuno-
blot as described above.
Fluorescence Microscopy of Bystander Apoptosis Induction
Fluorescent microscopy was used to visualize bystander
apoptosis induction in the adherent growing glioblastoma cell
line U87MG. U87MG.EGP2 target cells, brightly expressing
EGFP, were mixed at a 1:4 ratio with U87MG bystander cells
at a final concentration of 0.5  106 cells/well on Lab-Tek
chamber slides (Nalge Nunc International, Naperville, IL).
After overnight culture, spent medium was carefully aspirat-
ed and the mixed cell culture was subjected to treatment with
scFvC54:sTRAIL (300 ng/ml) for 16 hours, in the presence or
absence of MAb MOC31 (5 mg/ml) or MAb 2E5 (1 mg/ml),
respectively. After treatment, apoptosis induction apparent
from nuclear morphology was analyzed using the DNA-
binding dye Hoechst 33342 (Molecular Probes). Both nucle-
ar morphology and EGFP fluorescence were visualized
using a Quantimed 600S fluorescence microscope (Leica
Camera AG, Solms, Germany).
Quantification of Innocent Bystander Apoptosis in
Leukocytes
Leukocytes were isolated from EDTA anticoagulated
blood of healthy donors using the ammonium chloride meth-
od according to standard procedure. Briefly, blood was
diluted eight-fold with cold ammonium chloride buffer and
incubated for 10 minutes at 0jC, allowing the lysis of red
blood cells. Subsequently, leukocytes were collected by
centrifugation (1200g, 5 minutes). The above described
procedure was repeated to ensure complete lysis of all red
blood cells. Isolated leukocytes were resuspended (RPMI,
10% human pool serum) and mixed at a target-to-bystander
ratio of 1:1 with target Jurkat.EGP2 cells that were labeled
with the green fluorescent dye DiO (Molecular Probes).
Mixed cul tures were t reated for 16 hours wi th
scFvC54:sTRAIL in the presence or absence of MAb
MOC31 or MAb2E5. The degree of apoptosis induction after
treatment was analyzed by addition of the fluorescent DNA-
binding dye propidium iodide (PI) and quantification of the
percentage of PI-positive cells using flow cytometry.
Results
TRAIL-R Expression in EGP2-Transduced Cell Lines
Flow cytometric analysis of the retrovirally transduced cell
lines Jurkat.EGP2, Ramos.EGP2, and U87MG.EGP2 re-
vealed a strong homogeneous cell surface expression of
EGP2 and intracellular EGFP fluorescence (data not shown).
No significant differences in TRAIL receptor expression
patterns were found between parental and EGP2-trans-
duced cell lines (Table 1).
Target Cell–Restricted Apoptosis Induction by scFvC54:s
TRAIL
EGP2-negative bystander cells (Jurkat, Ramos, and
U87MG) were not susceptible to apoptosis induction by
scFvC54:sTRAIL. After prolonged treatment (16 hours) with
300 ng/ml scFvC54:sTRAIL, cell cultures contained only low
percentages of apoptotic cells (Figure 2A; 5%, 10%, and 3%,
for Jurkat, Ramos, and U87MG, respectively). When treat-
ment was performed in the presence of multimeric soluble
EGP2 (3.5 mg/ml), which secondarily cross-links scFvC54:s
TRAIL, a strong increase in the percentages of apoptotic
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cells was observed (92%, 84%, and 70% for Jurkat, Ramos,
and U87MG, respectively).
Treatment of EGP2-positive target cells (Jurkat.EGP2,
Ramos.EGP2, and U87MG.EGP2) with 300 ng/ml
scFvC54:sTRAIL induced a strong increase in percentage
of apoptotic cells (Figure 2B; 71%, 67%, and 65%, respec-
tively). Treatment of these EGP2-positive cells in the pres-
ence of EGP2-blocking MAb MOC31 strongly inhibited
apoptosis induction (16%, 13%, and 5%, for Jurkat.EGP2,
Ramos.EGP2, and U87MG.EGP2, respectively). Interest-
ingly, although levels of TRAIL receptor expression were
comparable for both parental and EGP2-transduced cell
lines, the sensitivity to apoptosis induction by scFvC54:
sTRAIL was somewhat reduced in the EGP2- transduced
cell lines. Reduced sensitivity of EGP2-transduced cells may
be related to the retroviral transduction procedure of these
cell lines, or the ectopic overexpression of EGP2.
Distinctive Quantification of Apoptosis Induction in Target
and Bystander Cells
When mixed cultures of Jurkat.EGP2 target cells and
Jurkat bystander cells were treated with scFvC54:sTRAIL,
strong apoptosis induction was observed in Jurkat.EGP2
target cells, ranging from 55% at target-to-bystander ratio
of 7:3 to 20% at ratio 1:100 (Figure 3A). Apoptosis induction
in Jurkat bystander cells ranged from 80% at ratio 7:3 to 17%
at the remarkably low ratio 1:100 (Figure 3B). Treatment of
bystander cells alone resulted in marginal induction of apo-
ptosis (7%). Percentages of apoptotic cells were strongly
reduced in both target and bystander cell populations when
treatment was performed in the presence of EGP2-blocking
MAb MOC31 (Figure 3, A and B). Analogously, treatment
with scFvC54:sTRAIL in the presence of TRAIL-neutralizing
MAb 2E5 resulted in complete abrogation of apoptosis
(Figure 3, A and B). Furthermore, when mixed cultures of
target and bystander cells were treated with the mock-
scFvH22:sTRAIL fusion protein containing the antibody frag-
ment domain scFvH22 of irrelevant specificity, no apoptosis
induction was found in Jurkat.EGP2 target or Jurkat bystand-
er cells (Figure 3C). Similar experiments with mixed cultures
of Ramos.EGP2 and Ramos, and the adherent cell lines
U87MG.EGP2 and U87MG, further confirmed that treatment
with scFvC54:sTRAIL potently induced both target and
bystander apoptosis, whereas treatment with mock-
scFvH22:sTRAIL did not lead to significant apoptosis induc-
tion in target or bystander cells (Figure 3C).
Target and Bystander Apoptosis Induction Is Caspase-8–
Dependent
In a mixed culture of Ramos.EGP2 target cells and
Ramos bystander cells (ratio 2:3), treatment with scFvC54:s
TRAIL resulted in bystander apoptosis induction up to 65%
(Figure 4A). However, treatment in the presence of the
specific caspase-8 inhibitor Z-IETD-FMK strongly inhibited
apoptosis induction in both target and bystander cells
(Figure 4A; 15% and 17%, respectively). Moreover, treat-
ment of a mixed culture of target cells (Ramos.EGP2) and
bystander cells ectopically overexpressing the caspase-8
Table 1. Flow Cytometric Analysis of TRAIL Receptor Expression on Target
and Bystander Cells.
Cell Line TRAIL-R1 TRAIL-R2 TRAIL-R3 TRAIL-R4
Ramos * * nd y
Ramos.EGP2 * * nd y
Jurkat nd * nd y
Jurkat.EGP2 nd * nd y
U87MG y z y y
U87MG.EGP2 y y y y
EGP2-positive target cells and EGP2-negative bystander cells were analyzed
for TRAIL receptor expression.
Expression of TRAIL receptors was classified as not detectable (nd) when
MFI was below 5.
*50 < MFI < 125.
y5 < MFI < 25.
z25 < MFI < 50.
Figure 2. Target cell – restricted apoptosis induction by scFvC54:sTRAIL. (A)
EGP2-negative bystander cells (Jurkat, Ramos, and U87MG) were treated
with scFvC54:sTRAIL alone to determine sensitivity to apoptosis induction
by noncross-linked scFvC54:sTRAIL. Additionally, cells were treated with
scFvC54:sTRAIL in the presence of multimeric sEGP2, which secondarily
cross-links scFvC54:sTRAIL, to determine intrinsic sensitivity to cross-linked
scFvC54:sTRAIL. (B) EGP2-positive target cells (Jurkat.EGP2, Ramos.
EGP2, and U87MG.EGP2) were treated with scFvC54:sTRAIL for 16 hours
in the presence or absence of target antigen–competing MAb MOC31.
Apoptosis induction was assessed by MTS assay as described in Materials
and Methods section. All values indicated in the graphs are the mean ± SEM
of four independent experiments.
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inhibitor c-FLIPL (Ramos.c-FLIPL) indicated that Ramos.c-
FLIPL bystander cells are largely resistant to the pro–
apoptotic bystander effect of scFvC54:sTRAIL (Figure 4B;
17%). The residual apoptosis induction observed for
Ramos.c-FLIPL bystander cells could be specifically
inhibited by coincubation with MAb MOC31.
Immunoblot Analysis of FACS-Sorted Target and
Bystander Cells
Posttreatment sorting of a mixed culture of Jurkat.EGP2
target and Jurkat bystander cells (ratio 1:1) allowed for the
separate evaluation of apoptotic features in target and
Figure 3. Separate evaluation of target cell and bystander cell apoptosis
induction by scFvC54:sTRAIL. Jurkat.EGP2 target and Jurkat bystander cells
were mixed at different target-to-bystander ratios and treated for 16 hours
with 300 ng/ml scFvC54:sTRAIL in the presence or absence of MAb MOC31
(5 g/ml) or MAb 2E5 (1 g/ml). After treatment, cells were harvested and
apoptosis induction was separately evaluated in (A) Jurkat.EGP2 target cells
and (B) Jurkat bystander cells. (C) Target antigen–dependent fratricide and
bystander apoptosis induction. Mixed cultures of target and bystander cell
combinations Jurkat.EGP2/Jurkat, Ramos.EGP2/Ramos, and U87MG.EGP2/
U87MG. EGP2 (at target-to-bystander ratio of 2:3) were treated with 300 ng/ml
scFvC54:sTRAIL (bars 1, 3, and 5), or with equal amounts of a scFv:sTRAIL
fusion protein of irrelevant specificity (mock-scFvH22:sTRAIL) (bars 2, 4,
and 6). Apoptosis induction was separately evaluated in target and by-
stander cells by loss of Dw as described in Materials and Methods section.
All values indicated in the graphs are mean ± SEM of four independent
experiments.
Figure 4. (A) Target cell and bystander cell apoptosis induction by
scFvC54:sTRAIL is caspase-8–specific. Ramos.EGP2 target cells and
Ramos bystander cells were mixed at target-to-bystander ratio of 2:3 and
treated with scFvC54:sTRAIL in the presence or absence of caspase-8
inhibitor, Z-IETD-FMK. After 16 hours, cells were harvested and apoptosis
induction was separately evaluated by loss of Dw in Ramos.EGP2 target cells
and Ramos bystander cells. (B) Ramos bystander cells ectopically over-
expressing c-FLIPL are largely insensitive to bystander apoptosis induction.
Ramos.EGP2 target cells were mixed at 2:3 target-to-bystander ratio with
either parental Ramos bystander cells or Ramos bystander cells ectopically
overexpressing cFLIPL (Ramos cFLIPL). Mixed cultures were subsequently
treated with 300 ng/ml scFvC54:sTRAIL in the presence or absence of MAb
MOC31, after which apoptosis induction was evaluated in bystander Ramos
or Ramos.cFLIPL by loss of Dw . All values indicated in the graph are mean ±
SEM of four independent experiments.
Potent Bystander Effect by scFvC54:sTRAIL Bremer et al. 641
Neoplasia . Vol. 6, No. 5, 2004
bystander cells. Treatment with scFvC54:sTRAIL induced a
clear activation of caspase-8 and caspase-3 in both Jurkat.
EGP2 target cells (Figure 5A, lane 2) and Jurkat bystander
cells (Figure 5B, lane 2). Activation of caspase-3 was ac-
companied by cleavage of its target protein PARP (Figure 5,
A and B, lane 2). Treatment in the presence of MAb MOC31
or MAb 2E5 inhibited caspase activation and PARP cleavage
in both target and bystander cells (Figure 5, A and B, lanes 3
and 4, respectively). Neither caspase activation nor PARP
cleavage was observed when Jurkat bystander cells were
treated in the absence of Jurkat.EGP2 target cells, even
when treatment was prolonged to 24 hours (data not shown).
Fluorescent Microscopy of Bystander Apoptosis Induction
Microscopic evaluation of untreated mixed cultures
revealed that adherent U87MG.EGP2 target cells and
U87MG bystander cells were interconnected by cellular
protrusions (Figure 6A). Protrusions coming from U87MG.
EGP2 target cells can be appreciated due to the EGFP
fluorescence present in the cytoplasm of these cells. When
a mixed culture of U87MG.EGP2 target cells and U87MG
bystander cells (ratio 1:4) was treated with 300 ng/ml
scFvC54:sTRAIL for 16 hours, pronounced apoptotic mor-
phologic features such as membrane blebbing and nuclear
condensation were visible in both target and bystander cells.
The efficacy of the bystander effect was apparent from the
fact that apoptotic morphology was observed in almost all
U87MG bystander cells (Figure 6B). Identical treatment in
the presence of either MAb MOC31 or MAb 2E5 strong-
ly inhibited the appearance of apoptotic morphology in
both U87MG.EGP2 target cells and U87MG bystander cells
(Figure 6, C and D).
No Innocent Bystander Apoptosis in Isolated Leukocytes
Treatment of mixed cultures of isolated leukocytes (inno-
cent bystander cells) and Jurkat.EGP2 cells with scFvC54:
sTRAIL did not lead to any significant induction of apoptosis
in the bystander leukocytes (Figure 7), whereas strong
apoptosis up to 46% was observed in Jurkat.EGP2 target
cells. Apoptosis in Jurkat.EGP2 was specifically inhibited
when treatment was performed in the presence of MAb
MOC31 or MAb 2E5.
Discussion
It has been shown that cross-linking of TRAIL receptors is
crucial for the efficient induction of apoptosis in tumor cells.
Previously, we reported on target cell–restricted fratricide
apoptosis induction by the fusion protein scFvC54:sTRAIL
due to the efficient cross-linking of agonistic TRAIL receptors
TRAIL-R1 and TRAIL-R2 [34]. In the present study, we
analyzed whether selective binding of scFvC54:sTRAIL to
EGP2-positive tumor cells could further be used to cross-link
TRAIL receptors on neighboring tumor cells devoid of EGP2
expression using mixed cell culture experiments. To this end,
we selected a series of cell lines that represent three major
human malignancies: acute lymphoblastic T-cell leukemia
(Jurkat), B-cell lymphoma (Ramos), and glioblastoma multi-
forme (U87MG), all of which are EGP2-negative and gener-
ated EGP2-positive target cells thereof by retroviral
transduction. Furthermore, we devised a method that
allowed for distinctive evaluation of apoptosis in target and
bystander cells.
All EGP2-negative bystander cell types used were fully
resistant to prolonged treatment with scFvC54:sTRAIL (16
hours, 300 ng/ml). However, when mixed cultures of EGP2-
positive target cells and corresponding EGP2-negative by-
stander cells were treated, potent pro–apoptotic effects of
up to 80% apoptosis induction were achieved in EGP2-
negative bystander cells (Figure 3A). Pro–apoptotic by-
stander activity of scFvC54:sTRAIL was observed for both
suspension tumor cell types (Jurkat and Ramos) and adher-
ent U87MG glioblastoma cells (Figure 3C).
Treatment of mixed cultures containing as little as 1% of
EGP2-positive target cells still showed significant apoptosis
induction of up to 17% in EGP2-negative bystander cells.
This clearly indicated that significant pro–apoptotic bystand-
er activity of scFvC54:sTRAIL can be achieved at low target-
to-bystander cell ratios. Treatment in the presence of an
EGP2-blocking antibody or a TRAIL-neutralizing antibody
strongly inhibited apoptosis induction in both target and
bystander cells at all ratios analyzed (Figure 3, A and B).
Figure 5. Separate evaluation of caspase activation and PARP cleavage in
Jurkat.EGP2 target cells and Jurkat bystander cells. Jurkat.EGP2 target cells
and Jurkat bystander cells were mixed at target-to-bystander ratio of 1:1 and
treated for 6 hours with scFvC54:sTRAIL in the presence or absence of MAb
MOC31 or MAb 2E5. After treatment, Jurkat.EGP2 target and Jurkat
bystander cells were separated by high-speed cell sorting, after which (A)
Jurkat.EGP2 target cells and (B) Jurkat bystander cells were separately
analyzed by immunoblot for caspase-8 activation, caspase-3 activation, and
PARP degradation. Arrows indicate bands corresponding to cleaved
caspase-8. Of note, in the caspase-8 blot of both Jurkat.EGP2 target cells
and Jurkat bystander cells, a specific band derived from the heavy chain of
MAb MOC31 is also visible.
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When treatment was performed using identical amounts
of a scFv:sTRAIL fusion protein of irrelevant specificity
(mock-scFvH22:sTRAIL), no induction of apoptosis was
observed (Figure 3C). Furthermore, apoptosis induction
was specifically absent in bystander cells that ecto-
pically overexpressed c-FLIPL, a specific inhibitor of death
receptor– induced apoptosis (Figure 4B). Immunoblot anal-
ysis of posttreatment-sorted target and bystander cells dem-
onstrated identical activation profiles of caspase-3 and
caspase-8, and cleavage of PARP (Figure 5, A and B).
Together, these results all indicated that both fratricide and
bystander apoptosis induction by scFvC54:sTRAIL are me-
diated by target cell–dependent intracellular cross-linking
of agonistic TRAIL receptors.
Microscopic evaluation of a mixed culture (ratio 1:4) of
adherent U87MG.EGP2 target cells and U87MG bystander
cells treated with scFvC54:sTRAIL visualized pronounced
apoptotic morphologic features (nuclear condensation and
membrane blebbing) in both target and bystander cells. The
strong bystander effect observed here might partly be due to
the fact that U87MG cells have extensive cellular protrusions
that appear to make multiple intracellular connections even
to more distant cells (Figure 6A). Possibly, this particular cell
morphology influences TRAIL receptor cross-linking by
scFvC54:sTRAIL between interconnected target cells and
bystander cells. It is tentative to speculate that scFv:sTRAIL
treatment of target cells with more extensive cellular protru-
sions may induce apoptosis in more distant bystander cells.
As discussed above, we analyzed the pro–apoptotic
bystander effect by scFvC54:sTRAIL down to extremely
low target-to-bystander cell ratios. We noticed that when
treatment was performed at ratios < 1:10, apoptosis induc-
tion in the target cells was partly inhibited (Figure 3A). It
appears that the presence of a vast majority of bystander
cells reduces direct cellular contacts between EGP2-positive
target cells, subsequently reducing fratricide apoptosis in-
duction of these cells. The inhibitory effect of bystander cells
on fratricide apoptosis induction in target cells was not
Figure 6. Visualization of bystander apoptosis by fluorescence microscopy. U87MG.EGP2 target cells and U87MG bystander cells were mixed at a target-to-
bystander ratio of 1:4 and precultured on chamber slides. Subsequently, the mixed cultures were subjected for 16 hours to treatment with (A) medium, (B)
scFvC54:sTRAIL (300 ng/ml), (C) MAb MOC31 (5 g/ml) + scFvC54:sTRAIL, and (D) MAb 2E5 (1 g/ml) + scFvC54:sTRAIL. After treatment, cells were stained
using the nuclear stain Hoechst and analyzed for characteristic apoptotic morphology. Target and bystander cells could be distinctly discriminated due to the
expression of green fluorescent protein by U87MG.EGP2 target cells only.
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observed at higher—and possibly more realistic—target-to-
bystander cell ratios.
Previously, bystander effects have been observed in
antibody-directed enzyme prodrug therapy (ADEPT) [41]
and virus-directed enzyme prodrug therapy (VDEPT)
[13,42], therapeutic approaches that target a nonhuman
prodrug-converting enzyme into tumor cells and involve the
transfer and diffusion of toxic metabolites from one cell to
another. Usually, the toxic metabolites produced using these
strategies cannot freely transit the cell membrane. Conse-
quently, these bystander effects chiefly depend on gap
junctional intracellular communication (GJIC) between target
and bystander tumor cells [14,43–45]. Unfortunately, most
cancer cells lack functional GJIC. The bystander apoptosis
activity described here for scFvC54:sTRAIL does not require
internalization, enzymatic conversion, diffusion, or commu-
nication (GJIC) between target and bystander cells.
An additional problem in both ADEPT and VDEPT
appears to be the preferential killing of targeted cells due
to their relative high intracellular concentration of the toxic
metabolite, resulting in a decreased bystander effect. In
contrast, the bystander activity of scFvC54:sTRAIL is likely
to be maintained during the whole process of target cell
apoptosis induction. Moreover, apoptosis of a given target
cell can yield numerous minute apoptotic bodies with intact
EGP2-positive cellular membranes. In vitro, target cell–
derived apoptotic bodies displaying scFvC54:sTRAIL might
continue to contribute to the cross-linking of TRAIL receptors
and potentially disseminate the bystander effect to more
distant tumor cells. The presence and subsequent contribu-
tion of such apoptotic bodies to the bystander effect studied
here remain to be clarified. However, in vivo, it is likely that
phagocytosing cells of the immune system rapidly scavenge
such apoptotic bodies before additional bystander apoptosis
induction is initiated.
We wondered whether the potent pro–apoptotic bystand-
er effect of scFvC54:sTRAIL might also result in the killing of
‘‘innocent bystander’’ cells such as normal blood cells.
Therefore, we added freshly isolated leukocytes to various
bystander experiments and found no significant signs of ap-
optosis induction in the various blood cell types (Figure 7).
This indicates that, at least in this experimental setting,
scFvC54:sTRAIL has retained its tumor-selective apoptosis
activity with no signs of innocent bystander apoptosis induc-
tion. Nevertheless, from the present study, it cannot be
excluded that scFvC54:sTRAIL might exert toxic or innocent
bystander effects toward other normal cells and tissues.
Toxicity studies of scFvC54:sTRAIL can possibly be per-
formed in our human EGP2 transgenic mouse model [46] in
which human EGP2 expression displays authentic expres-
sion patterns in mouse epithelia. In conclusion, this is the first
example of target cell–dependent bystander apoptotic ac-
tivity by a scFv:sTRAIL fusion protein. Further development
of this new principle is warranted for TRAIL and antibody-
based therapy of human cancers that escape current anti-
body-based therapy due to heterogeneous target antigen
expression.
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